Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:( Sunitinib). Showing records 1 – 30 of 33 total matches.

[1] [2]

Search Limiters

Last 2 Years | English Only

▼ Search Limiters


University of Vienna

1. Novicky, Astrid. Anticancer activity potentiation of the cyclohexadepsipeptides Enniatin B and Beauvericin by the protein kinase inhibitors-inhibitors Sorafenib and Sunitinib.

Degree: 2014, University of Vienna

 Beauvericin (Bea) and Enniatin B (Enn B) sind sekundäre Metabolite der Schimmelpilz Gattung Fusarium und kommen als häufige Verunreinigungen in verschiedenen Getreidearten vor[9-12]. Basierend auf… (more)

Subjects/Keywords: 44.38 Pharmakologie; Beauvericin / Enniatin B / Sorafenib / Sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Novicky, A. (2014). Anticancer activity potentiation of the cyclohexadepsipeptides Enniatin B and Beauvericin by the protein kinase inhibitors-inhibitors Sorafenib and Sunitinib. (Thesis). University of Vienna. Retrieved from http://othes.univie.ac.at/33764/

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Novicky, Astrid. “Anticancer activity potentiation of the cyclohexadepsipeptides Enniatin B and Beauvericin by the protein kinase inhibitors-inhibitors Sorafenib and Sunitinib.” 2014. Thesis, University of Vienna. Accessed February 21, 2019. http://othes.univie.ac.at/33764/.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Novicky, Astrid. “Anticancer activity potentiation of the cyclohexadepsipeptides Enniatin B and Beauvericin by the protein kinase inhibitors-inhibitors Sorafenib and Sunitinib.” 2014. Web. 21 Feb 2019.

Vancouver:

Novicky A. Anticancer activity potentiation of the cyclohexadepsipeptides Enniatin B and Beauvericin by the protein kinase inhibitors-inhibitors Sorafenib and Sunitinib. [Internet] [Thesis]. University of Vienna; 2014. [cited 2019 Feb 21]. Available from: http://othes.univie.ac.at/33764/.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Novicky A. Anticancer activity potentiation of the cyclohexadepsipeptides Enniatin B and Beauvericin by the protein kinase inhibitors-inhibitors Sorafenib and Sunitinib. [Thesis]. University of Vienna; 2014. Available from: http://othes.univie.ac.at/33764/

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Pennsylvania

2. Truitt, Rachel Elizabeth. Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues.

Degree: 2017, University of Pennsylvania

 ABSTRACT DEVELOPING A PRECLINICAL MODEL OF HUMAN SUNITINIB CARDIOTOXICITY TO ASSESS THE ROLE OF MECHANICAL LOADING USING ENGINEERED CARDIAC MICROTISSUES Rachel Elizabeth Truitt Kenneth B.… (more)

Subjects/Keywords: cardio-oncology; cardiotoxicity; sunitinib; tissue engineering; Biomedical

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Truitt, R. E. (2017). Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues. (Thesis). University of Pennsylvania. Retrieved from https://repository.upenn.edu/edissertations/2615

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Truitt, Rachel Elizabeth. “Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues.” 2017. Thesis, University of Pennsylvania. Accessed February 21, 2019. https://repository.upenn.edu/edissertations/2615.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Truitt, Rachel Elizabeth. “Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues.” 2017. Web. 21 Feb 2019.

Vancouver:

Truitt RE. Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues. [Internet] [Thesis]. University of Pennsylvania; 2017. [cited 2019 Feb 21]. Available from: https://repository.upenn.edu/edissertations/2615.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Truitt RE. Developing A Preclinical Model Of Human Sunitinib Cardiotoxicity To Assess The Role Of Mechanical Loading Using Engineered Cardiac Microtissues. [Thesis]. University of Pennsylvania; 2017. Available from: https://repository.upenn.edu/edissertations/2615

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Kyoto University / 京都大学

3. Shibasaki, Noboru. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma : IL13RA2は、淡明型腎細胞癌のスニチニブ抵抗性獲得に関与する。.

Degree: 博士(医学), 2016, Kyoto University / 京都大学

新制・課程博士

甲第19888号

医博第4137号

Subjects/Keywords: Renal Cell Carcinoma; sunitinib; IL13RA2; sunitinib resistance

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Shibasaki, N. (2016). Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma : IL13RA2は、淡明型腎細胞癌のスニチニブ抵抗性獲得に関与する。. (Thesis). Kyoto University / 京都大学. Retrieved from http://hdl.handle.net/2433/215954 ; http://dx.doi.org/10.14989/doctor.k19888

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Shibasaki, Noboru. “Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma : IL13RA2は、淡明型腎細胞癌のスニチニブ抵抗性獲得に関与する。.” 2016. Thesis, Kyoto University / 京都大学. Accessed February 21, 2019. http://hdl.handle.net/2433/215954 ; http://dx.doi.org/10.14989/doctor.k19888.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Shibasaki, Noboru. “Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma : IL13RA2は、淡明型腎細胞癌のスニチニブ抵抗性獲得に関与する。.” 2016. Web. 21 Feb 2019.

Vancouver:

Shibasaki N. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma : IL13RA2は、淡明型腎細胞癌のスニチニブ抵抗性獲得に関与する。. [Internet] [Thesis]. Kyoto University / 京都大学; 2016. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/2433/215954 ; http://dx.doi.org/10.14989/doctor.k19888.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Shibasaki N. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma : IL13RA2は、淡明型腎細胞癌のスニチニブ抵抗性獲得に関与する。. [Thesis]. Kyoto University / 京都大学; 2016. Available from: http://hdl.handle.net/2433/215954 ; http://dx.doi.org/10.14989/doctor.k19888

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


University of Helsinki

4. Björkstén, Sofie. Hypertension, kardiotoxicitet och njursvikt i samband med tyrosinkinashämmaren sunitinib.

Degree: Farmaceutiska fakulteten, 2011, University of Helsinki

 Nybildning av blodkärl från tidigare existerande kärl, angiogenes, är ett väsentligt skede vid tumörtillväxt. Denna process regleras av bland annat tillväxtfaktorer, var av den vaskulära… (more)

Subjects/Keywords: VEGF; tyrosinkinas; tyrosinkinashämmare; sunitinib; kaloribegränsning; tyrosine kinase; tyrosine kinase inhibitor; sunitinib; caloric restriction; Farmakologi; Pharmacology; Farmakologia

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Björkstén, S. (2011). Hypertension, kardiotoxicitet och njursvikt i samband med tyrosinkinashämmaren sunitinib. (Masters Thesis). University of Helsinki. Retrieved from http://hdl.handle.net/10138/28723

Chicago Manual of Style (16th Edition):

Björkstén, Sofie. “Hypertension, kardiotoxicitet och njursvikt i samband med tyrosinkinashämmaren sunitinib.” 2011. Masters Thesis, University of Helsinki. Accessed February 21, 2019. http://hdl.handle.net/10138/28723.

MLA Handbook (7th Edition):

Björkstén, Sofie. “Hypertension, kardiotoxicitet och njursvikt i samband med tyrosinkinashämmaren sunitinib.” 2011. Web. 21 Feb 2019.

Vancouver:

Björkstén S. Hypertension, kardiotoxicitet och njursvikt i samband med tyrosinkinashämmaren sunitinib. [Internet] [Masters thesis]. University of Helsinki; 2011. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/10138/28723.

Council of Science Editors:

Björkstén S. Hypertension, kardiotoxicitet och njursvikt i samband med tyrosinkinashämmaren sunitinib. [Masters Thesis]. University of Helsinki; 2011. Available from: http://hdl.handle.net/10138/28723

5. Shibasaki, Noboru. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma .

Degree: 2016, Kyoto University

Subjects/Keywords: Renal Cell Carcinoma; sunitinib; IL13RA2; sunitinib resistance

Page 1 Page 2

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Shibasaki, N. (2016). Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma . (Thesis). Kyoto University. Retrieved from http://hdl.handle.net/2433/215954

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Shibasaki, Noboru. “Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma .” 2016. Thesis, Kyoto University. Accessed February 21, 2019. http://hdl.handle.net/2433/215954.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Shibasaki, Noboru. “Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma .” 2016. Web. 21 Feb 2019.

Vancouver:

Shibasaki N. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma . [Internet] [Thesis]. Kyoto University; 2016. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/2433/215954.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Shibasaki N. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma . [Thesis]. Kyoto University; 2016. Available from: http://hdl.handle.net/2433/215954

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Universiteit Utrecht

6. Klümpen, H.J. Personalized medicine of targeted anti-cancer drugs.

Degree: 2012, Universiteit Utrecht

 Medicine is becoming more and more tailored and that certainly applies to therapies for cancer. The researcher has looked at the genetic profile of the… (more)

Subjects/Keywords: Farmacie; pharmacogenetics; pharmacodynamics; targeted therapies; mTOR inhibitors; imatinib; sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Klümpen, H. J. (2012). Personalized medicine of targeted anti-cancer drugs. (Doctoral Dissertation). Universiteit Utrecht. Retrieved from http://dspace.library.uu.nl:8080/handle/1874/234354

Chicago Manual of Style (16th Edition):

Klümpen, H J. “Personalized medicine of targeted anti-cancer drugs.” 2012. Doctoral Dissertation, Universiteit Utrecht. Accessed February 21, 2019. http://dspace.library.uu.nl:8080/handle/1874/234354.

MLA Handbook (7th Edition):

Klümpen, H J. “Personalized medicine of targeted anti-cancer drugs.” 2012. Web. 21 Feb 2019.

Vancouver:

Klümpen HJ. Personalized medicine of targeted anti-cancer drugs. [Internet] [Doctoral dissertation]. Universiteit Utrecht; 2012. [cited 2019 Feb 21]. Available from: http://dspace.library.uu.nl:8080/handle/1874/234354.

Council of Science Editors:

Klümpen HJ. Personalized medicine of targeted anti-cancer drugs. [Doctoral Dissertation]. Universiteit Utrecht; 2012. Available from: http://dspace.library.uu.nl:8080/handle/1874/234354


Case Western Reserve University

7. Ko, Jennifer S. Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib.

Degree: PhD, Pathology, 2009, Case Western Reserve University

  Tumor-driven accumulation of myeloid-derived suppressor cells (MDSC) facilitates tumor immune evasion via T-cell inhibition, therefore limiting therapeutic approaches. MDSC accumulate in tumor-bearing hosts via… (more)

Subjects/Keywords: Immunology; Myeloid-derived Suppressor Cells; sunitinib; immune suppression; T cell; tumor

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Ko, J. S. (2009). Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib. (Doctoral Dissertation). Case Western Reserve University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=case1259869673

Chicago Manual of Style (16th Edition):

Ko, Jennifer S. “Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib.” 2009. Doctoral Dissertation, Case Western Reserve University. Accessed February 21, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=case1259869673.

MLA Handbook (7th Edition):

Ko, Jennifer S. “Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib.” 2009. Web. 21 Feb 2019.

Vancouver:

Ko JS. Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib. [Internet] [Doctoral dissertation]. Case Western Reserve University; 2009. [cited 2019 Feb 21]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=case1259869673.

Council of Science Editors:

Ko JS. Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib. [Doctoral Dissertation]. Case Western Reserve University; 2009. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=case1259869673


Penn State University

8. Liu, Dai. Combination of sunitinib-targeted therapy with T cell immunotherapy for eradicating established liver tumors.

Degree: PhD, Molecular Medicine, 2013, Penn State University

 Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and its incidence has been increasing in the US over the past decades. The… (more)

Subjects/Keywords: Regulatory T cells; Hepatocellular carcinoma; CD8 T cells; Sunitinib; Immunotherapy

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Liu, D. (2013). Combination of sunitinib-targeted therapy with T cell immunotherapy for eradicating established liver tumors. (Doctoral Dissertation). Penn State University. Retrieved from https://etda.libraries.psu.edu/catalog/18808

Chicago Manual of Style (16th Edition):

Liu, Dai. “Combination of sunitinib-targeted therapy with T cell immunotherapy for eradicating established liver tumors.” 2013. Doctoral Dissertation, Penn State University. Accessed February 21, 2019. https://etda.libraries.psu.edu/catalog/18808.

MLA Handbook (7th Edition):

Liu, Dai. “Combination of sunitinib-targeted therapy with T cell immunotherapy for eradicating established liver tumors.” 2013. Web. 21 Feb 2019.

Vancouver:

Liu D. Combination of sunitinib-targeted therapy with T cell immunotherapy for eradicating established liver tumors. [Internet] [Doctoral dissertation]. Penn State University; 2013. [cited 2019 Feb 21]. Available from: https://etda.libraries.psu.edu/catalog/18808.

Council of Science Editors:

Liu D. Combination of sunitinib-targeted therapy with T cell immunotherapy for eradicating established liver tumors. [Doctoral Dissertation]. Penn State University; 2013. Available from: https://etda.libraries.psu.edu/catalog/18808


University of Debrecen

9. Blumberg, Jonathan. Neoadjuvant Administration Of Sunitinib In Metastatic Renal Cell Carcinoma .

Degree: DE – Általános Orvostudományi Kar, University of Debrecen

administration of neoadjuvant sunitinib treatment in patients with metastatic renal carcinoma and tumor thrombus in the inferior vena cava. Advisors/Committee Members: Berczi, Csaba (advisor), Debreceni Egyetem::Általános Orvostudományi Kar::Urológiai Klinika (advisor).

Subjects/Keywords: SUNITINIB; metastatic renal cell carcinoma

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Blumberg, J. (n.d.). Neoadjuvant Administration Of Sunitinib In Metastatic Renal Cell Carcinoma . (Thesis). University of Debrecen. Retrieved from http://hdl.handle.net/2437/229979

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Blumberg, Jonathan. “Neoadjuvant Administration Of Sunitinib In Metastatic Renal Cell Carcinoma .” Thesis, University of Debrecen. Accessed February 21, 2019. http://hdl.handle.net/2437/229979.

Note: this citation may be lacking information needed for this citation format:
No year of publication.
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Blumberg, Jonathan. “Neoadjuvant Administration Of Sunitinib In Metastatic Renal Cell Carcinoma .” Web. 21 Feb 2019.

Note: this citation may be lacking information needed for this citation format:
No year of publication.

Vancouver:

Blumberg J. Neoadjuvant Administration Of Sunitinib In Metastatic Renal Cell Carcinoma . [Internet] [Thesis]. University of Debrecen; [cited 2019 Feb 21]. Available from: http://hdl.handle.net/2437/229979.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.

Council of Science Editors:

Blumberg J. Neoadjuvant Administration Of Sunitinib In Metastatic Renal Cell Carcinoma . [Thesis]. University of Debrecen; Available from: http://hdl.handle.net/2437/229979

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation
No year of publication.


University of Manitoba

10. Mozolevska, Viktoriya. The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity.

Degree: Physiology and Pathophysiology, 2016, University of Manitoba

 Background: Targeted agents Bevacizumab and Sunitinib are associated with an increased risk of cardiovascular complications in colorectal and renal cancer settings, respectively. Objective: To elucidate… (more)

Subjects/Keywords: Cardio-oncology; Cardiotoxicity; Bevacizumab; Sunitinib; Heart failure; Renin-angiotensin system

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mozolevska, V. (2016). The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity. (Masters Thesis). University of Manitoba. Retrieved from http://hdl.handle.net/1993/32419

Chicago Manual of Style (16th Edition):

Mozolevska, Viktoriya. “The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity.” 2016. Masters Thesis, University of Manitoba. Accessed February 21, 2019. http://hdl.handle.net/1993/32419.

MLA Handbook (7th Edition):

Mozolevska, Viktoriya. “The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity.” 2016. Web. 21 Feb 2019.

Vancouver:

Mozolevska V. The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity. [Internet] [Masters thesis]. University of Manitoba; 2016. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/1993/32419.

Council of Science Editors:

Mozolevska V. The cardioprotective role of renin-angiotensin system antagonists in the prevention of Bevacizumab and Sunitinib mediated cardiotoxicity. [Masters Thesis]. University of Manitoba; 2016. Available from: http://hdl.handle.net/1993/32419


University of Melbourne

11. Nguyen, Linh My. Effects of chemotherapy on colorectal liver metastases.

Degree: 2012, University of Melbourne

 Background: Colorectal cancer (CRC) is the fourth most frequently occurring cancer in the world. Despite optimum surgical endeavours, many patients will develop disease recurrence. Treatments… (more)

Subjects/Keywords: OXi4503; Sunitinib; epithelial to mesenchymal transition; colorectal liver metastases

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Nguyen, L. M. (2012). Effects of chemotherapy on colorectal liver metastases. (Doctoral Dissertation). University of Melbourne. Retrieved from http://hdl.handle.net/11343/37303

Chicago Manual of Style (16th Edition):

Nguyen, Linh My. “Effects of chemotherapy on colorectal liver metastases.” 2012. Doctoral Dissertation, University of Melbourne. Accessed February 21, 2019. http://hdl.handle.net/11343/37303.

MLA Handbook (7th Edition):

Nguyen, Linh My. “Effects of chemotherapy on colorectal liver metastases.” 2012. Web. 21 Feb 2019.

Vancouver:

Nguyen LM. Effects of chemotherapy on colorectal liver metastases. [Internet] [Doctoral dissertation]. University of Melbourne; 2012. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/11343/37303.

Council of Science Editors:

Nguyen LM. Effects of chemotherapy on colorectal liver metastases. [Doctoral Dissertation]. University of Melbourne; 2012. Available from: http://hdl.handle.net/11343/37303


Vrije Universiteit Amsterdam

12. Veldt, A.A.M. van der. Sunitinib for advanced renal cell cancer: Clinical and pharmacodynamic aspects .

Degree: 2012, Vrije Universiteit Amsterdam

Subjects/Keywords: Sunitinib; renal cell cancer

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Veldt, A. A. M. v. d. (2012). Sunitinib for advanced renal cell cancer: Clinical and pharmacodynamic aspects . (Doctoral Dissertation). Vrije Universiteit Amsterdam. Retrieved from http://hdl.handle.net/1871/38166

Chicago Manual of Style (16th Edition):

Veldt, A A M van der. “Sunitinib for advanced renal cell cancer: Clinical and pharmacodynamic aspects .” 2012. Doctoral Dissertation, Vrije Universiteit Amsterdam. Accessed February 21, 2019. http://hdl.handle.net/1871/38166.

MLA Handbook (7th Edition):

Veldt, A A M van der. “Sunitinib for advanced renal cell cancer: Clinical and pharmacodynamic aspects .” 2012. Web. 21 Feb 2019.

Vancouver:

Veldt AAMvd. Sunitinib for advanced renal cell cancer: Clinical and pharmacodynamic aspects . [Internet] [Doctoral dissertation]. Vrije Universiteit Amsterdam; 2012. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/1871/38166.

Council of Science Editors:

Veldt AAMvd. Sunitinib for advanced renal cell cancer: Clinical and pharmacodynamic aspects . [Doctoral Dissertation]. Vrije Universiteit Amsterdam; 2012. Available from: http://hdl.handle.net/1871/38166

13. Kammerer-Jacquet, Solène-Florence. Carcinome à cellules claires du rein : phénotype métastatique et résistance aux thérapies ciblées : Clear cell renal cell carcinoma : metastatic phenotype and resistance to anti-angiogenic therapy.

Degree: Docteur es, Biologie et sciences de la santé, 2016, Rennes 1

 Le carcinome rénal à cellules claires (ccRCC) est la tumeur du rein la plus fréquente. Il se caractérise par une inactivation fréquente du gène suppresseur… (more)

Subjects/Keywords: Carcinomes à cellules claires du rein; Métastases synchrones; Métastases métachrones; Sunitinib; Cabozantinib; Nivolumab; Réponse; Résistance; Clear cell renal cell carcinoma; Synchronous metastasis; Metachronous metastasis; Sunitinib; Cabozantinib; Nivolumab; Response; Resistance

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Kammerer-Jacquet, S. (2016). Carcinome à cellules claires du rein : phénotype métastatique et résistance aux thérapies ciblées : Clear cell renal cell carcinoma : metastatic phenotype and resistance to anti-angiogenic therapy. (Doctoral Dissertation). Rennes 1. Retrieved from http://www.theses.fr/2016REN1B038

Chicago Manual of Style (16th Edition):

Kammerer-Jacquet, Solène-Florence. “Carcinome à cellules claires du rein : phénotype métastatique et résistance aux thérapies ciblées : Clear cell renal cell carcinoma : metastatic phenotype and resistance to anti-angiogenic therapy.” 2016. Doctoral Dissertation, Rennes 1. Accessed February 21, 2019. http://www.theses.fr/2016REN1B038.

MLA Handbook (7th Edition):

Kammerer-Jacquet, Solène-Florence. “Carcinome à cellules claires du rein : phénotype métastatique et résistance aux thérapies ciblées : Clear cell renal cell carcinoma : metastatic phenotype and resistance to anti-angiogenic therapy.” 2016. Web. 21 Feb 2019.

Vancouver:

Kammerer-Jacquet S. Carcinome à cellules claires du rein : phénotype métastatique et résistance aux thérapies ciblées : Clear cell renal cell carcinoma : metastatic phenotype and resistance to anti-angiogenic therapy. [Internet] [Doctoral dissertation]. Rennes 1; 2016. [cited 2019 Feb 21]. Available from: http://www.theses.fr/2016REN1B038.

Council of Science Editors:

Kammerer-Jacquet S. Carcinome à cellules claires du rein : phénotype métastatique et résistance aux thérapies ciblées : Clear cell renal cell carcinoma : metastatic phenotype and resistance to anti-angiogenic therapy. [Doctoral Dissertation]. Rennes 1; 2016. Available from: http://www.theses.fr/2016REN1B038


Université Paris-Sud – Paris XI

14. Broutin, Sophie. Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde : Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma.

Degree: Docteur es, Cancérologie, 2011, Université Paris-Sud – Paris XI

Le cancer médullaire de la thyroïde (CMT), qui représente 5 à 8% des cancers de la thyroïde, est issu de la transformation maligne des cellules… (more)

Subjects/Keywords: Cancer médullaire de la thyroïde; Inhibiteurs d’activité kinase; Sunitinib; Vandetanib; Puces à ADN; RPPA; Biomarqueur; Réponse thérapeutique.; Medullary Thyroid Carcinoma; Tyrosine kinase inhibitors; Sunitinib; Vandetanib; Microarray; RPPA; Biomarker; Therapeutic response

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Broutin, S. (2011). Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde : Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma. (Doctoral Dissertation). Université Paris-Sud – Paris XI. Retrieved from http://www.theses.fr/2011PA11T053

Chicago Manual of Style (16th Edition):

Broutin, Sophie. “Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde : Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma.” 2011. Doctoral Dissertation, Université Paris-Sud – Paris XI. Accessed February 21, 2019. http://www.theses.fr/2011PA11T053.

MLA Handbook (7th Edition):

Broutin, Sophie. “Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde : Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma.” 2011. Web. 21 Feb 2019.

Vancouver:

Broutin S. Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde : Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma. [Internet] [Doctoral dissertation]. Université Paris-Sud – Paris XI; 2011. [cited 2019 Feb 21]. Available from: http://www.theses.fr/2011PA11T053.

Council of Science Editors:

Broutin S. Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde : Molecular pharmacology of sunitinib and vandetanib, two tyrosine kinase inhibitors, in Medullary Thyroid Carcinoma. [Doctoral Dissertation]. Université Paris-Sud – Paris XI; 2011. Available from: http://www.theses.fr/2011PA11T053


Anna University

15. Syamantak Majumder. Study of the role of hepatic stellate cells in liver fibrosis;.

Degree: 2013, Anna University

In chronic liver injury, activated hepatic stellate cells (HSC) are the major source of collagens that facilitate liver fibrosis. Drugs and stem cells targeting patho-physiology… (more)

Subjects/Keywords: Hepatic stellate cells; stem cell; liver fibrosis; sunitinib; everolimus; mTOR; endothelial cells

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Majumder, S. (2013). Study of the role of hepatic stellate cells in liver fibrosis;. (Thesis). Anna University. Retrieved from http://shodhganga.inflibnet.ac.in/handle/10603/11527

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Majumder, Syamantak. “Study of the role of hepatic stellate cells in liver fibrosis;.” 2013. Thesis, Anna University. Accessed February 21, 2019. http://shodhganga.inflibnet.ac.in/handle/10603/11527.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Majumder, Syamantak. “Study of the role of hepatic stellate cells in liver fibrosis;.” 2013. Web. 21 Feb 2019.

Vancouver:

Majumder S. Study of the role of hepatic stellate cells in liver fibrosis;. [Internet] [Thesis]. Anna University; 2013. [cited 2019 Feb 21]. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/11527.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Majumder S. Study of the role of hepatic stellate cells in liver fibrosis;. [Thesis]. Anna University; 2013. Available from: http://shodhganga.inflibnet.ac.in/handle/10603/11527

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


McMaster University

16. Trabelsi, Salma. THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS.

Degree: MSc, 2011, McMaster University

Breast cancer is the most common cancer among Canadian women with one in nine women expected to develop breast cancer in their lifetime. Until… (more)

Subjects/Keywords: Breast cancer; cancer stem cells; sunitinib; MMTV-neu tumors; Cancer Biology; Cancer Biology

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Trabelsi, S. (2011). THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS. (Masters Thesis). McMaster University. Retrieved from http://hdl.handle.net/11375/10478

Chicago Manual of Style (16th Edition):

Trabelsi, Salma. “THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS.” 2011. Masters Thesis, McMaster University. Accessed February 21, 2019. http://hdl.handle.net/11375/10478.

MLA Handbook (7th Edition):

Trabelsi, Salma. “THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS.” 2011. Web. 21 Feb 2019.

Vancouver:

Trabelsi S. THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS. [Internet] [Masters thesis]. McMaster University; 2011. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/11375/10478.

Council of Science Editors:

Trabelsi S. THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS. [Masters Thesis]. McMaster University; 2011. Available from: http://hdl.handle.net/11375/10478

17. Verhoest, Grégory. Développement et mise au point de modèles murins de xénogreffe de carcinome rénal à cellules claires, et évaluation de la réponse de l’association d’un antagoniste des récepteurs à l’angiotensine-II au sunitinib. : Development of different xenograft mouse models of clear cell renal cell carcinoma, and analysis of the efficacy ofangiotensin-II type 1 receptor antagonists combined with sunitinib.

Degree: Docteur es, Biologie et sciences de la santé, 2014, Rennes 1

Contexte : Les carcinomes rénaux à cellules claires (ccRCC) sont des tumeurs particulièrement agressives et de mauvais pronostic lorsqu’elles sont métastatiques. L’apport des traitements anti-angiogéniques et… (more)

Subjects/Keywords: Cancer du rein; Traitements anti-angiogéniques; Inhibiteurs du système rénine-angiotensine; Sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Verhoest, G. (2014). Développement et mise au point de modèles murins de xénogreffe de carcinome rénal à cellules claires, et évaluation de la réponse de l’association d’un antagoniste des récepteurs à l’angiotensine-II au sunitinib. : Development of different xenograft mouse models of clear cell renal cell carcinoma, and analysis of the efficacy ofangiotensin-II type 1 receptor antagonists combined with sunitinib. (Doctoral Dissertation). Rennes 1. Retrieved from http://www.theses.fr/2014REN1B005

Chicago Manual of Style (16th Edition):

Verhoest, Grégory. “Développement et mise au point de modèles murins de xénogreffe de carcinome rénal à cellules claires, et évaluation de la réponse de l’association d’un antagoniste des récepteurs à l’angiotensine-II au sunitinib. : Development of different xenograft mouse models of clear cell renal cell carcinoma, and analysis of the efficacy ofangiotensin-II type 1 receptor antagonists combined with sunitinib.” 2014. Doctoral Dissertation, Rennes 1. Accessed February 21, 2019. http://www.theses.fr/2014REN1B005.

MLA Handbook (7th Edition):

Verhoest, Grégory. “Développement et mise au point de modèles murins de xénogreffe de carcinome rénal à cellules claires, et évaluation de la réponse de l’association d’un antagoniste des récepteurs à l’angiotensine-II au sunitinib. : Development of different xenograft mouse models of clear cell renal cell carcinoma, and analysis of the efficacy ofangiotensin-II type 1 receptor antagonists combined with sunitinib.” 2014. Web. 21 Feb 2019.

Vancouver:

Verhoest G. Développement et mise au point de modèles murins de xénogreffe de carcinome rénal à cellules claires, et évaluation de la réponse de l’association d’un antagoniste des récepteurs à l’angiotensine-II au sunitinib. : Development of different xenograft mouse models of clear cell renal cell carcinoma, and analysis of the efficacy ofangiotensin-II type 1 receptor antagonists combined with sunitinib. [Internet] [Doctoral dissertation]. Rennes 1; 2014. [cited 2019 Feb 21]. Available from: http://www.theses.fr/2014REN1B005.

Council of Science Editors:

Verhoest G. Développement et mise au point de modèles murins de xénogreffe de carcinome rénal à cellules claires, et évaluation de la réponse de l’association d’un antagoniste des récepteurs à l’angiotensine-II au sunitinib. : Development of different xenograft mouse models of clear cell renal cell carcinoma, and analysis of the efficacy ofangiotensin-II type 1 receptor antagonists combined with sunitinib. [Doctoral Dissertation]. Rennes 1; 2014. Available from: http://www.theses.fr/2014REN1B005

18. Guérin, Olivier. Intérêts en thérapeutique du ciblage des récepteurs à l'Epidermal Growth Factor(EGFR) et des récepteurs au Vascular Endothelial Growth Factor(VEGFR)dans le cancer de prostate hormono-résistant et docetaxel-résistant : etudes précliniques. : Therapeutic's interest of epidermal Growth Factor Receptors(EGFR) and Vascular Endothelial Growth Factor Receptors(VEGFR) targeting for hormone-refractory prostate cancert : preclinical studies.

Degree: Docteur es, Pathologie humaine, 2010, Aix-Marseille 2

Le cancer de la prostate, premier cancer chez l’homme en France, a bénéficié largement des avancées thérapeutiques de la chirurgie, de la chimiothérapie, de la… (more)

Subjects/Keywords: Cancer de prostate hormono-résistant; Cetuximab; Sunitinib; Vandetanib; Associations de traitements; Modèle animal; Phases précliniques

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Guérin, O. (2010). Intérêts en thérapeutique du ciblage des récepteurs à l'Epidermal Growth Factor(EGFR) et des récepteurs au Vascular Endothelial Growth Factor(VEGFR)dans le cancer de prostate hormono-résistant et docetaxel-résistant : etudes précliniques. : Therapeutic's interest of epidermal Growth Factor Receptors(EGFR) and Vascular Endothelial Growth Factor Receptors(VEGFR) targeting for hormone-refractory prostate cancert : preclinical studies. (Doctoral Dissertation). Aix-Marseille 2. Retrieved from http://www.theses.fr/2010AIX20670

Chicago Manual of Style (16th Edition):

Guérin, Olivier. “Intérêts en thérapeutique du ciblage des récepteurs à l'Epidermal Growth Factor(EGFR) et des récepteurs au Vascular Endothelial Growth Factor(VEGFR)dans le cancer de prostate hormono-résistant et docetaxel-résistant : etudes précliniques. : Therapeutic's interest of epidermal Growth Factor Receptors(EGFR) and Vascular Endothelial Growth Factor Receptors(VEGFR) targeting for hormone-refractory prostate cancert : preclinical studies.” 2010. Doctoral Dissertation, Aix-Marseille 2. Accessed February 21, 2019. http://www.theses.fr/2010AIX20670.

MLA Handbook (7th Edition):

Guérin, Olivier. “Intérêts en thérapeutique du ciblage des récepteurs à l'Epidermal Growth Factor(EGFR) et des récepteurs au Vascular Endothelial Growth Factor(VEGFR)dans le cancer de prostate hormono-résistant et docetaxel-résistant : etudes précliniques. : Therapeutic's interest of epidermal Growth Factor Receptors(EGFR) and Vascular Endothelial Growth Factor Receptors(VEGFR) targeting for hormone-refractory prostate cancert : preclinical studies.” 2010. Web. 21 Feb 2019.

Vancouver:

Guérin O. Intérêts en thérapeutique du ciblage des récepteurs à l'Epidermal Growth Factor(EGFR) et des récepteurs au Vascular Endothelial Growth Factor(VEGFR)dans le cancer de prostate hormono-résistant et docetaxel-résistant : etudes précliniques. : Therapeutic's interest of epidermal Growth Factor Receptors(EGFR) and Vascular Endothelial Growth Factor Receptors(VEGFR) targeting for hormone-refractory prostate cancert : preclinical studies. [Internet] [Doctoral dissertation]. Aix-Marseille 2; 2010. [cited 2019 Feb 21]. Available from: http://www.theses.fr/2010AIX20670.

Council of Science Editors:

Guérin O. Intérêts en thérapeutique du ciblage des récepteurs à l'Epidermal Growth Factor(EGFR) et des récepteurs au Vascular Endothelial Growth Factor(VEGFR)dans le cancer de prostate hormono-résistant et docetaxel-résistant : etudes précliniques. : Therapeutic's interest of epidermal Growth Factor Receptors(EGFR) and Vascular Endothelial Growth Factor Receptors(VEGFR) targeting for hormone-refractory prostate cancert : preclinical studies. [Doctoral Dissertation]. Aix-Marseille 2; 2010. Available from: http://www.theses.fr/2010AIX20670


University of Manitoba

19. Bordun, Kimberly-Ann. Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity.

Degree: Physiology, 2014, University of Manitoba

 Background: Although Bevacizumab (BVZ) and Sunitinib (SNT) prolong survival in cancer patients, an unanticipated side-effect is cardiotoxicity. Early indices of left ventricular (LV) systolic dysfunction… (more)

Subjects/Keywords: Cancer; Cardiomyopathy; Bevacizumab; Sunitinib; Cardiotoxicity; Echocardiography; Tissue velocity imaging; Biomarkers; Hemodynamics; Oxidative stress

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Bordun, K. (2014). Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity. (Masters Thesis). University of Manitoba. Retrieved from http://hdl.handle.net/1993/23884

Chicago Manual of Style (16th Edition):

Bordun, Kimberly-Ann. “Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity.” 2014. Masters Thesis, University of Manitoba. Accessed February 21, 2019. http://hdl.handle.net/1993/23884.

MLA Handbook (7th Edition):

Bordun, Kimberly-Ann. “Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity.” 2014. Web. 21 Feb 2019.

Vancouver:

Bordun K. Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity. [Internet] [Masters thesis]. University of Manitoba; 2014. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/1993/23884.

Council of Science Editors:

Bordun K. Early detection of broken hearts in cancer: Bevacizumab and Sunitinib mediated cardiotoxicity. [Masters Thesis]. University of Manitoba; 2014. Available from: http://hdl.handle.net/1993/23884

20. Marrero Cofino, Gisela. Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity.

Degree: M. Sc., Sciences des radiations et imagerie biomédicale, 2014, Université de Sherbrooke

Sunitinib (Sutent®) is a multitargeted, small molecule receptor tyrosine kinase inhibitor used as an anti-cancer drug. It has increased the overall survival rate of metastatic… (more)

Subjects/Keywords: Tomographie d'émission par positrons; Sunitinib; Cardiotoxicité; Fraction d'éjection ventriculaire gauche; FEVG; Positron emission tomography; Cardiotoxicity; LVEF

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Marrero Cofino, G. (2014). Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity. (Masters Thesis). Université de Sherbrooke. Retrieved from http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_5939.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/5939/1/Marrero_Cofino_Gisela_MSc_2014.pdf

Chicago Manual of Style (16th Edition):

Marrero Cofino, Gisela. “Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity.” 2014. Masters Thesis, Université de Sherbrooke. Accessed February 21, 2019. http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_5939.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/5939/1/Marrero_Cofino_Gisela_MSc_2014.pdf.

MLA Handbook (7th Edition):

Marrero Cofino, Gisela. “Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity.” 2014. Web. 21 Feb 2019.

Vancouver:

Marrero Cofino G. Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity. [Internet] [Masters thesis]. Université de Sherbrooke; 2014. [cited 2019 Feb 21]. Available from: http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_5939.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/5939/1/Marrero_Cofino_Gisela_MSc_2014.pdf.

Council of Science Editors:

Marrero Cofino G. Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity. [Masters Thesis]. Université de Sherbrooke; 2014. Available from: http://www.collectionscanada.gc.ca/obj/thesescanada/vol2/QSHERU/TC-QSHERU-11143_5939.pdf ; http://savoirs.usherbrooke.ca/bitstream/11143/5939/1/Marrero_Cofino_Gisela_MSc_2014.pdf


Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ)

21. Fragkoulidi, Anna. Μελέτη της αγγειογένεσης και της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα μετά από χορήγηση του SU011248 σε ασθενείς με προχωρημένο καρκίνωμα κεφαλής και του τραχήλου.

Degree: 2013, Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ)

The goal of the present thesis was to study the efficacy and pharmacokinetics of sunitinib and its correlation with the immunohistochemical expression of angiogenic factors… (more)

Subjects/Keywords: Υποτροπιάζον καρκίνωμα κεφαλής και τραχήλου; Σουνιτινίμπη; Αγγειογένεση; Ανοσοϊστοχημική έκφραση; Recurrent head and neck carcinoma; Sunitinib; Angiogenesis; Immunihistochemical expression

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Fragkoulidi, A. (2013). Μελέτη της αγγειογένεσης και της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα μετά από χορήγηση του SU011248 σε ασθενείς με προχωρημένο καρκίνωμα κεφαλής και του τραχήλου. (Thesis). Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Retrieved from http://hdl.handle.net/10442/hedi/36943

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Fragkoulidi, Anna. “Μελέτη της αγγειογένεσης και της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα μετά από χορήγηση του SU011248 σε ασθενείς με προχωρημένο καρκίνωμα κεφαλής και του τραχήλου.” 2013. Thesis, Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ). Accessed February 21, 2019. http://hdl.handle.net/10442/hedi/36943.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Fragkoulidi, Anna. “Μελέτη της αγγειογένεσης και της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα μετά από χορήγηση του SU011248 σε ασθενείς με προχωρημένο καρκίνωμα κεφαλής και του τραχήλου.” 2013. Web. 21 Feb 2019.

Vancouver:

Fragkoulidi A. Μελέτη της αγγειογένεσης και της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα μετά από χορήγηση του SU011248 σε ασθενείς με προχωρημένο καρκίνωμα κεφαλής και του τραχήλου. [Internet] [Thesis]. Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ); 2013. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/10442/hedi/36943.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Fragkoulidi A. Μελέτη της αγγειογένεσης και της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα μετά από χορήγηση του SU011248 σε ασθενείς με προχωρημένο καρκίνωμα κεφαλής και του τραχήλου. [Thesis]. Aristotle University Of Thessaloniki (AUTH); Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης (ΑΠΘ); 2013. Available from: http://hdl.handle.net/10442/hedi/36943

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Université de Sherbrooke

22. Marrero Cofino, Gisela. Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity .

Degree: 2014, Université de Sherbrooke

 Abstract: Sunitinib (Sutent®) is a multitargeted, small molecule receptor tyrosine kinase inhibitor used as an anti-cancer drug. It has increased the overall survival rate of… (more)

Subjects/Keywords: Tomographie d'émission par positrons; Sunitinib; Cardiotoxicité; Fraction d'éjection ventriculaire gauche; FEVG; Positron emission tomography; Cardiotoxicity; LVEF

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Marrero Cofino, G. (2014). Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity . (Masters Thesis). Université de Sherbrooke. Retrieved from http://hdl.handle.net/11143/5939

Chicago Manual of Style (16th Edition):

Marrero Cofino, Gisela. “Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity .” 2014. Masters Thesis, Université de Sherbrooke. Accessed February 21, 2019. http://hdl.handle.net/11143/5939.

MLA Handbook (7th Edition):

Marrero Cofino, Gisela. “Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity .” 2014. Web. 21 Feb 2019.

Vancouver:

Marrero Cofino G. Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity . [Internet] [Masters thesis]. Université de Sherbrooke; 2014. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/11143/5939.

Council of Science Editors:

Marrero Cofino G. Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity . [Masters Thesis]. Université de Sherbrooke; 2014. Available from: http://hdl.handle.net/11143/5939

23. Klümpen, H.J. Personalized medicine of targeted anti-cancer drugs.

Degree: 2012, University Utrecht

 Medicine is becoming more and more tailored and that certainly applies to therapies for cancer. The researcher has looked at the genetic profile of the… (more)

Subjects/Keywords: pharmacogenetics; pharmacodynamics; targeted therapies; mTOR inhibitors; imatinib; sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Klümpen, H. J. (2012). Personalized medicine of targeted anti-cancer drugs. (Doctoral Dissertation). University Utrecht. Retrieved from http://dspace.library.uu.nl/handle/1874/234354 ; URN:NBN:NL:UI:10-1874-234354 ; urn:isbn:978-90-3935738-5 ; URN:NBN:NL:UI:10-1874-234354 ; http://dspace.library.uu.nl/handle/1874/234354

Chicago Manual of Style (16th Edition):

Klümpen, H J. “Personalized medicine of targeted anti-cancer drugs.” 2012. Doctoral Dissertation, University Utrecht. Accessed February 21, 2019. http://dspace.library.uu.nl/handle/1874/234354 ; URN:NBN:NL:UI:10-1874-234354 ; urn:isbn:978-90-3935738-5 ; URN:NBN:NL:UI:10-1874-234354 ; http://dspace.library.uu.nl/handle/1874/234354.

MLA Handbook (7th Edition):

Klümpen, H J. “Personalized medicine of targeted anti-cancer drugs.” 2012. Web. 21 Feb 2019.

Vancouver:

Klümpen HJ. Personalized medicine of targeted anti-cancer drugs. [Internet] [Doctoral dissertation]. University Utrecht; 2012. [cited 2019 Feb 21]. Available from: http://dspace.library.uu.nl/handle/1874/234354 ; URN:NBN:NL:UI:10-1874-234354 ; urn:isbn:978-90-3935738-5 ; URN:NBN:NL:UI:10-1874-234354 ; http://dspace.library.uu.nl/handle/1874/234354.

Council of Science Editors:

Klümpen HJ. Personalized medicine of targeted anti-cancer drugs. [Doctoral Dissertation]. University Utrecht; 2012. Available from: http://dspace.library.uu.nl/handle/1874/234354 ; URN:NBN:NL:UI:10-1874-234354 ; urn:isbn:978-90-3935738-5 ; URN:NBN:NL:UI:10-1874-234354 ; http://dspace.library.uu.nl/handle/1874/234354

24. Gotink, K.J. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors.

Degree: 2016, NARCIS

Subjects/Keywords: Lysosome; Resistance; Sunitinib; Tumor cell; Tyrosine Kinase Inhibitor

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Gotink, K. J. (2016). Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors. (Doctoral Dissertation). NARCIS. Retrieved from https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; urn:nbn:nl:ui:31-1871/55173 ; e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; 1871/55173 ; urn:nbn:nl:ui:31-1871/55173 ; https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a

Chicago Manual of Style (16th Edition):

Gotink, K J. “Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors.” 2016. Doctoral Dissertation, NARCIS. Accessed February 21, 2019. https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; urn:nbn:nl:ui:31-1871/55173 ; e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; 1871/55173 ; urn:nbn:nl:ui:31-1871/55173 ; https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a.

MLA Handbook (7th Edition):

Gotink, K J. “Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors.” 2016. Web. 21 Feb 2019.

Vancouver:

Gotink KJ. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors. [Internet] [Doctoral dissertation]. NARCIS; 2016. [cited 2019 Feb 21]. Available from: https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; urn:nbn:nl:ui:31-1871/55173 ; e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; 1871/55173 ; urn:nbn:nl:ui:31-1871/55173 ; https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a.

Council of Science Editors:

Gotink KJ. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors. [Doctoral Dissertation]. NARCIS; 2016. Available from: https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; urn:nbn:nl:ui:31-1871/55173 ; e1139cce-e5f7-4afc-b66d-ff93a6e6046a ; 1871/55173 ; urn:nbn:nl:ui:31-1871/55173 ; https://research.vu.nl/en/publications/e1139cce-e5f7-4afc-b66d-ff93a6e6046a


Vrije Universiteit Amsterdam

25. Mijn, J.C. van der. New biomarkers and treatment strategies in renal cell cancer .

Degree: 2016, Vrije Universiteit Amsterdam

Subjects/Keywords: oncology; renal cell cancer; sunitinib; predictive biomarkers

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mijn, J. C. v. d. (2016). New biomarkers and treatment strategies in renal cell cancer . (Doctoral Dissertation). Vrije Universiteit Amsterdam. Retrieved from http://hdl.handle.net/1871/54810

Chicago Manual of Style (16th Edition):

Mijn, J C van der. “New biomarkers and treatment strategies in renal cell cancer .” 2016. Doctoral Dissertation, Vrije Universiteit Amsterdam. Accessed February 21, 2019. http://hdl.handle.net/1871/54810.

MLA Handbook (7th Edition):

Mijn, J C van der. “New biomarkers and treatment strategies in renal cell cancer .” 2016. Web. 21 Feb 2019.

Vancouver:

Mijn JCvd. New biomarkers and treatment strategies in renal cell cancer . [Internet] [Doctoral dissertation]. Vrije Universiteit Amsterdam; 2016. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/1871/54810.

Council of Science Editors:

Mijn JCvd. New biomarkers and treatment strategies in renal cell cancer . [Doctoral Dissertation]. Vrije Universiteit Amsterdam; 2016. Available from: http://hdl.handle.net/1871/54810

26. Gotink, K.J. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors .

Degree: 2016, Vrije Universiteit Amsterdam

Subjects/Keywords: Lysosome; Resistance; Sunitinib; Tumor cell; Tyrosine Kinase Inhibitor

Page 1

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Gotink, K. J. (2016). Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors . (Doctoral Dissertation). Vrije Universiteit Amsterdam. Retrieved from http://hdl.handle.net/1871/55173

Chicago Manual of Style (16th Edition):

Gotink, K J. “Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors .” 2016. Doctoral Dissertation, Vrije Universiteit Amsterdam. Accessed February 21, 2019. http://hdl.handle.net/1871/55173.

MLA Handbook (7th Edition):

Gotink, K J. “Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors .” 2016. Web. 21 Feb 2019.

Vancouver:

Gotink KJ. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors . [Internet] [Doctoral dissertation]. Vrije Universiteit Amsterdam; 2016. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/1871/55173.

Council of Science Editors:

Gotink KJ. Tumor cell resistance to antiangiogenic receptor tyrosine kinase inhibitors . [Doctoral Dissertation]. Vrije Universiteit Amsterdam; 2016. Available from: http://hdl.handle.net/1871/55173


University of Oxford

27. Fewkes, Natasha Marie. Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases.

Degree: PhD, 2012, University of Oxford

 Immune cell niches are microenvironments that support the survival of specific hematopoietic cells. The size of a given niche is dependent on survival and proliferation… (more)

Subjects/Keywords: 616.07; Immunology; Medical Sciences; Biology (medical sciences); Dendritic cell research; History of childhood; Interleukin 7; Hematopoietic Stem cell transplant; Sunitinib; tolerance; Dendritic cell; niche

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Fewkes, N. M. (2012). Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases. (Doctoral Dissertation). University of Oxford. Retrieved from http://ora.ox.ac.uk/objects/uuid:cdd4e490-3b49-4f7e-839e-3a48ae34aafe ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.588400

Chicago Manual of Style (16th Edition):

Fewkes, Natasha Marie. “Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases.” 2012. Doctoral Dissertation, University of Oxford. Accessed February 21, 2019. http://ora.ox.ac.uk/objects/uuid:cdd4e490-3b49-4f7e-839e-3a48ae34aafe ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.588400.

MLA Handbook (7th Edition):

Fewkes, Natasha Marie. “Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases.” 2012. Web. 21 Feb 2019.

Vancouver:

Fewkes NM. Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases. [Internet] [Doctoral dissertation]. University of Oxford; 2012. [cited 2019 Feb 21]. Available from: http://ora.ox.ac.uk/objects/uuid:cdd4e490-3b49-4f7e-839e-3a48ae34aafe ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.588400.

Council of Science Editors:

Fewkes NM. Modulation of immune cell niches for therapeutics in cancer and inflammatory diseases. [Doctoral Dissertation]. University of Oxford; 2012. Available from: http://ora.ox.ac.uk/objects/uuid:cdd4e490-3b49-4f7e-839e-3a48ae34aafe ; http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.588400

28. Lee, Lok Yan. Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations.

Degree: PhD, 2016, De Montfort University

 This study aims at tackling some of the problems often encountered in photostability testing and liquid formulation development. Three anti-cancer drugs will be employed as… (more)

Subjects/Keywords: 616.99; photostability; photodegradation; anti-cancer; dacarbazine; axitinib; sunitinib; photostability; stabilization; formulation; F-order; modelling; kinetic; photokinetic; degradation; cyclodextrin; nanosponge; actinometer; characterisation; complexation; complex; quantum yields; photoreversible; isomers; isotherm; spectroscopic; fluorimetry; stiochiometry; association constant; binding constant

Page 1 Page 2 Page 3

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Lee, L. Y. (2016). Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations. (Doctoral Dissertation). De Montfort University. Retrieved from http://hdl.handle.net/2086/12188

Chicago Manual of Style (16th Edition):

Lee, Lok Yan. “Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations.” 2016. Doctoral Dissertation, De Montfort University. Accessed February 21, 2019. http://hdl.handle.net/2086/12188.

MLA Handbook (7th Edition):

Lee, Lok Yan. “Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations.” 2016. Web. 21 Feb 2019.

Vancouver:

Lee LY. Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations. [Internet] [Doctoral dissertation]. De Montfort University; 2016. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/2086/12188.

Council of Science Editors:

Lee LY. Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations. [Doctoral Dissertation]. De Montfort University; 2016. Available from: http://hdl.handle.net/2086/12188

29. Δημητρόπουλος, Κωνσταντίνος. Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού HER.

Degree: 2013, University of Patras

 Το γλοιοβλάστωμα αποτελεί έναν από τους πιο θανατηφόρους τύπους καρκίνου για τον άνθρωπο δεδομένου ότι ο μέσος όρος επιβίωσης είναι 12-15 μήνες. Η συμβατική θεραπεία… (more)

Subjects/Keywords: Γλοιοβλάστωμα; Αναστολείς κινάσης τυροσίνης; Μετάσταση; Πολλαπλασιασμός; Ιντεγκρίνες; Αγγειογένεση; Απόπτωση; Υποδοχείς αυξητικών παραγόντων; Σημεία εστιακής προσκόλλησης; Ανοσοφθορισμός; Κυτταρικές σειρές; 616.994 060 724; Glioblastoma; Tyrosine kinase inhibitors; Metastasis; Cell growth; Integrins; Confocal; FAK; Apoptosis; EGFR; VEGFR; Lapatinib; Sunitinib

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Δημητρόπουλος, . (2013). Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού HER. (Doctoral Dissertation). University of Patras. Retrieved from http://hdl.handle.net/10889/6606

Chicago Manual of Style (16th Edition):

Δημητρόπουλος, Κωνσταντίνος. “Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού HER.” 2013. Doctoral Dissertation, University of Patras. Accessed February 21, 2019. http://hdl.handle.net/10889/6606.

MLA Handbook (7th Edition):

Δημητρόπουλος, Κωνσταντίνος. “Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού HER.” 2013. Web. 21 Feb 2019.

Vancouver:

Δημητρόπουλος . Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού HER. [Internet] [Doctoral dissertation]. University of Patras; 2013. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/10889/6606.

Council of Science Editors:

Δημητρόπουλος . Μελέτη της μοριακής στόχευσης κυττάρων του πλειόμορφου γλοιοβλαστώματος με αναστολείς της αγγειογένεσης και μορίων του μονοπατιού HER. [Doctoral Dissertation]. University of Patras; 2013. Available from: http://hdl.handle.net/10889/6606


Vrije Universiteit Amsterdam

30. Vroling, L. Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients .

Degree: 2011, Vrije Universiteit Amsterdam

Subjects/Keywords: Angiogenesis; angiogenesis-inhibitors; biomarkers; VEGFR2; CECs; EPCs; cancer; hypoxia; endothelial cells; progenitors; bevacizumab; sorafenib; erlotinib; sunitinib; ECFCs

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Vroling, L. (2011). Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients . (Doctoral Dissertation). Vrije Universiteit Amsterdam. Retrieved from http://hdl.handle.net/1871/18586

Chicago Manual of Style (16th Edition):

Vroling, L. “Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients .” 2011. Doctoral Dissertation, Vrije Universiteit Amsterdam. Accessed February 21, 2019. http://hdl.handle.net/1871/18586.

MLA Handbook (7th Edition):

Vroling, L. “Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients .” 2011. Web. 21 Feb 2019.

Vancouver:

Vroling L. Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients . [Internet] [Doctoral dissertation]. Vrije Universiteit Amsterdam; 2011. [cited 2019 Feb 21]. Available from: http://hdl.handle.net/1871/18586.

Council of Science Editors:

Vroling L. Circulating endothelial and progenitor cells during anti-angiogenic treatment in cancer patients . [Doctoral Dissertation]. Vrije Universiteit Amsterdam; 2011. Available from: http://hdl.handle.net/1871/18586

[1] [2]

.